Korea United Pharmaceutical(68,800 +3.61%)Announced on the 4th that it has entered the domestic clinical phase 2 of a candidate substance for non-alcoholic steatohepatitis (NASH) treatment.
Korea United Pharmaceutical has been conducting research in 2016 by transferring the technology related to the treatment of non-alcoholic steatohepatitis using the active ingredient of gold formulation from the Seoul National University Industry-Academic Cooperation Foundation. It is explained that it has been involved in a number of national projects since 2017 by receiving a patent on the use of Auranofin for preventing and treating liver fibrosis and cirrhosis.
After the completion of phase 2 clinical trials, it is planning to export technology to global pharmaceutical companies.
Oranopine is used under the approval of the US Food and Drug Administration (FDA) as a treatment for rheumatoid arthritis. Korea United Pharm has conducted prior research using the characteristics of oranopine. Through this, it was identified that oranopine is a multicellular targeting drug that acts on both hepatocytes and astrocytes as well as macrophages that make up the liver.
Oranofin can be used to prevent and treat liver fibrosis and cirrhosis by promoting the transformation of’M2′ macrophages responsible for immune function in the body and increasing the expression of a gene called’TREM-2′, and as a treatment for non-alcoholic steatohepatitis. The company is expecting that there will be.
Korea United Pharmaceutical has secured the patent rights of Oranopine in many countries. A U.S. patent was registered in May of last year, and rights can be guaranteed until 2035. In 2019, a Japanese patent was registered. In addition, patents have been applied for and are being examined in major countries such as China and Vietnam.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution